To study the pharmacokinetic characteristics and safety of ALA after single administration at different doses in patients with moderate to severe acne vulgaris, to understand the pharmacokinetic behavior of the drug and its active metabolite PpIX in humans, and to provide a reference for the formulation of treatment plans for subsequent clinical trials

Start Date12 Jan 2021

Sponsor / Collaborator

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

CTR20190540 / CompletedPhase 1/2

ALA治疗中重度寻常性痤疮的安全性、耐受性和初步疗效的临床试验

[Translation] A clinical trial on the safety, tolerability and preliminary efficacy of ALA in the treatment of moderate to severe acne vulgaris

探索ALA联合LED光动力治疗仪治疗中重度寻常性痤疮的安全性、耐受性及临床疗效，探索ALA的治疗剂量（敷药浓度和封包时间）

[Translation]

To explore the safety, tolerability and clinical efficacy of ALA combined with LED photodynamic therapy in the treatment of moderate to severe acne vulgaris, and to explore the therapeutic dose of ALA (drug concentration and packing time)

Start Date11 Jul 2019

Sponsor / Collaborator

Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.

EUCTR2015-000265-32-FI / Not yet recruitingPhase 4IIT

Daylight photodynamic therapy for actinic keratoses: a multicentre study comparing two photosensitizers (BF-200 ALA versus MAL)

Start Date08 Apr 2015

Sponsor / Collaborator-

100 Clinical Results associated with α-Linolenic acid

100 Translational Medicine associated with α-Linolenic acid

100 Patents (Medical) associated with α-Linolenic acid

Literatures (Medical) associated with α-Linolenic acid

01 Dec 2024·Journal of Food Science and Technology

A low n-6/n-3 PUFA ratio and high level of dietary ɑ-linolenic acid improves sleep behavior in mice with insomnia

Article

Author: Wu, Jia-Kai ; Yu, Li-Qin ; Zhang, Hua-Nan ; Li, Fei-Fei ; Liu, Yu-Qing ; Zhu, Jie ; Ning, Er-Juan ; Liang, Shen

Camelina sativa oil (CSO) and Semen Ziziphi Spinosae oil (SZSO) are functional oils that have beneficial effects on brain health. This study evaluated the sedative and hypnotic effects of vegetable oils with various n - 6/n - 3 polyunsaturated fatty acids (PUFA) ratios and ɑ-linolenic acid (ALA) contents to mice. The n - 6/n - 3 PUFA ratios of CSO (CSO:SZSO = 1:0, 1.8 g/kg), SZSO (CSO:SZSO = 0:1, 1.8 g/kg), CSO-SZSO-L (CSO:SZSO = 1:1, 1.8 g/kg), and CSO-SZSO-H (CSO:SZSO = 1:1, 3.6 g/kg) were 0.51, 140, 1.69, and 1.69, respectively. The doses of ALA administered to mice with p-chlorophenylalanine-induced insomnia were approximately 0.64, 50 × 10^-4, 0.32, and 0.64 g/kg, respectively. The mice were administered CSO, SZSO, and a low-dose combination of CSO and SZSO for seven days with no obvious hypnotic effects. However, the administration of a high-dose combination of CSO and SZSO significantly prolonged sleep duration in mice with induced insomnia and inhibited the serum levels of corticotropin-releasing hormone, adrenocorticotropic hormone, and cortisol. Interestingly, there were no significant effects on the structure and function of the hippocampal tissue. The results indicated that the anti-insomnia effects of these vegetable oils were positively correlated with a low n - 6/n - 3 PUFA ratio and the absolute amount of ALA.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13197-024-06004-1.

01 Nov 2024·Plant Cell Reports

Exogenous 5-aminolevulinic acid enhanced saline-alkali tolerance in pepper seedlings by regulating photosynthesis, oxidative damage, and glutathione metabolism

Article

Author: Wang, Jiqing ; Yang, Sizhen ; Wang, Hu ; Chen, Chunlin ; Li, Meng ; Li, Baixue ; Li, Jinling ; Wang, Xueting ; Du, Qingjie ; Xiao, HuaiJuan ; Wang, Yichao ; Li, Juanqi

KEY MESSAGEA plant growth regulator, 5-aminolevulinic acid, enhanced the saline-alkali tolerance via photosynthetic, oxidative-reduction, and glutathione metabolism pathways in pepper seedlings. Saline-alkali stress is a prominent environmental problem, hindering growth and development of pepper. 5-Aminolevulinic acid (ALA) application effectively improves plant growth status under various abiotic stresses. Here, we evaluated morphological, physiological, and transcriptomic differences in saline-alkali-stressed pepper seedlings after ALA application to explore the impact of ALA on saline-alkali stress. The results indicated that saline-alkali stress inhibited plant growth, decreased biomass and photosynthesis, altered the osmolyte content and antioxidant system, and increased reactive oxygen species (ROS) accumulation and proline content in pepper seedlings. Conversely, the application of exogenous ALA alleviated this damage by increasing the photosynthetic rate, osmolyte content, antioxidant enzyme activity, and antioxidants, including superoxide dismutase, catalase, glutathione reductase, and glutathione peroxidase, and reducing glutathione to reduce ROS accumulation and malonaldehyde content. Moreover, the transcriptomic analysis revealed the differentially expressed genes were mainly associated with photosynthesis, oxidation-reduction process, and glutathione metabolism in saline-alkali stress + ALA treatment compared to saline-alkali treatment. Among them, the change in expression level in CaGST, CaGR, and CaGPX was close to the variation of corresponding enzyme activity. Collectively, our findings revealed the alleviating effect of ALA on saline-alkali stress in pepper seedlings, broadening the application of ALA and providing a feasible strategy for utilize saline-alkali soil.

17 Oct 2024·Journal of clinical medicine

Extracorporeal Photopheresis with 5-Aminolevulinic Acid in Crohn's Disease-A First-in-Human Phase I/II Study.

Article

Author: Peng, Qian ; Kleinauskas, Andrius ; Vasovic, Vlada ; Warloe, Trond ; Aandahl, Astrid ; Juzenas, Petras ; Espeland, Kristian ; Darvekar, Sagar ; Jahnsen, Jørgen ; Christensen, Eidi ; Ulvær, Andreas

Background/Objectives: With the increasing prevalence of Crohn's disease (CD), treatment options for patients who fail conventional and advanced therapy are highly needed. Therefore, we explored the safety and efficacy of extracorporeal photopheresis (ECP) using 5-aminolevulinic acid (ALA) and blue light (405 nm). Methods: Patients with active CD who failed or were intolerant to biological therapy were eligible. Mononuclear cells (90 mL) were collected from each patient using a Spectra Optia^® apheresis system and diluted with 100 mL of 0.9% sodium chloride in a collection bag. The cells were incubated with ALA at a concentration of 3 millimolar (mM) for 60 min ex vivo and illumination with an LED blue light (405 nm) source (BLUE-PIT^®) before reinfusion to the patient. Recording of vital signs and adverse events were regularly performed. At week 13, we assessed the patients with colonoscopy, the Harvey Bradshaw Index (HBI), the Inflammatory Bowel disease Health Related Quality of Life Questionnaire, and the measurement of serum C-reactive protein and fecal calprotectin (FC) levels. Biopsies of the intestines were taken for immunohistochemistry. Results: Seven patients were included. Four patients completed the treatments, with a total of 24 treatments. Three of the four patients achieved a favorable response, including a lower HBI, lower FC levels, and/or endoscopic improvement. No significant adverse events were observed. The remaining three patients received only one, three, or five treatments due to technical difficulties, medical reasons, or the withdrawal of informed consent. Conclusions: ALA-based ECP appears safe and seems to give some clinical improvement for the patients with active CD who failed to respond to conventional and advanced therapies.

100 Deals associated with α-Linolenic acid

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	Preclinical	CN	Nanchong Central Hospital	22 May 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data